Dogwood Therapeutics Inc. (NASDAQ: DWTX) announced the start of a 12-week extension study for its Halneuron drug to treat chemotherapy-induced ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE